BCT.TO BriaCell (TSX) +43% pre-market Jan 14 2026: clinical result fuels trade

BCT.TO stock leads pre-market top gainers on Jan 14 2026 after a clinical update pushed trading interest higher. The share price opened at CAD 16.49, last printed CAD 15.22, up 43.05% on volume of 63,629 shares. The move follows a GlobeNewswire release reporting an 11-month sustained complete resolution of a lung metastasis in a Bria-OTS patient. We break down what the spike means for investors on the TSX and what to watch next as the biotech sector digests the news.